मेथोकार्बामोल के इंटरैक्शन

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (एस्टाज़ोलम लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ओलिसेरिडिन लेबल, बॉक्स्ड चेतावनी)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (कीटोकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (कोडीन लेबल, बॉक्स्ड चेतावनी)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोबाज़ाम लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (क्लोरप्रोमाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (गैबापेंटिन लेबल, चेतावनियां और सावधानियां)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (टेपेंटाडोल लेबल, बॉक्स्ड चेतावनी)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (टेमाज़ेपाम लेबल, चेतावनियां)

CONTRAINDICATIONS A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage. (ट्राइफ्लुओपेराज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (डारुनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (नालबुफिन लेबल, बॉक्स्ड चेतावनी)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

Depolarizing Muscle Relaxants Use of neostigmine to reverse the effects of depolarizing muscle relaxants such as succinylcholine is not recommended, because it may prolong the phase-1 block. (नियोस्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown… (परफेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (पेंटाज़ोसिन और नालोक्सोन लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

THE NEUROTOXICITY OF POLYMYXIN B SULFATE CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/OR MUSCLE RELAXANTS. (पॉलीमिक्सिन B लेबल, बॉक्स्ड चेतावनी)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. (प्रोक्लोरपेराज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

…obstruction, spasms in the urinary tract collection system, inactivation of nerve and muscle cells after administration of drugs to relax the muscles (depolarization block after depolarizing muscle relaxants), in case of intoxication due to “irreversibly acting” cholinesterase inhibitors (drugs used to treat dementia), intoxication with phosphoric acid esters or barbiturates. (फाइसोस्टिग्मिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CNS depressants: Closely monitor for sedation and respiratory depression. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (फोसएम्प्रेनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (बेलाडोना और ओपियम लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूप्रेनॉर्फिन लेबल, बॉक्स्ड चेतावनी)

Examples: phenelzine, tranylcypromine, linezolid Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (मॉर्फिन लेबल, बॉक्स्ड चेतावनी)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (रिटोनाविर लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (रेमिफेंटानिल लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (लेवॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (लोपिनाविर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

शराब को नींद लाने वाली दवाओं (ओपिओइड, बेंज़ोडायज़ेपिन, नींद की दवाएं, मसल रिलैक्सेंट) के साथ लेने से खतरनाक स्तर का उनींदापन, धीमी सांस और ओवरडोज़ हो सकता है। (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (सेलेजिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (हाइड्रोमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission Co-administration of XEOMIN and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., tubocurarine-type muscle relaxants) should only be performed with caution as these agents may potentiate the effect of the toxin. (इनकोबोटुलिनमटॉक्सिनA लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (एट्राक्यूरियम लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) Possible increased responsiveness to the muscle relaxant. (एनालाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Skeletal Muscle Relaxants Amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine) due to hypokalemia. (एम्फोटेरिसिन B लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (ओनाबोटुलिनमटॉक्सिनA लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) − Possible increased responsiveness to muscle relaxants such as curare derivatives. (कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Curariform muscle relaxants (e.g., tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral. (कोलिस्टिमेथेट लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine) - possible increased responsiveness to the muscle relaxant. (क्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

The effects of the following drugs may be potentiated when given together with triamterene: antihypertensive medication, other diuretics, preanesthetic and anesthetic agents, skeletal muscle relaxants (non-depolarizing). (ट्रायमटेरिन लेबल, दवाओं के इंटरैक्शन)

Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine (an effect attributed to potassium loss); consequently, caution should be observed in patients undergoing surgery. (ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

…malformation, central nervous system tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides)… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (पोसाकोनाज़ोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (बिसोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, सावधानियां)

Digitalis glycosides: Thiazide-induced hypokalemia or hypomagnesemia may predispose the patients to digoxin toxicity Skeletal muscle relaxants: Possible increased responsiveness to muscle relaxants such as curare derivatives. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (बोटुलिनम टॉक्सिन टाइप A लेबल, दवाओं के इंटरैक्शन)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

In such patients, a peripheral nerve stimulator and use of a small test dose may be of value in monitoring the response to administration of muscle relaxants. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

In such patients, a peripheral nerve stimulator and use of a small test dose may be of value in monitoring the response to administration of muscle relaxants. (वेक्यूरोनियम लेबल, चेतावनियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine). (साइक्लोफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1 ) (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant may result. (स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Dopamine agonists, such as bromocriptine, and muscle relaxants, such as dantrolene, are often used in the treatment of NMS; however, their effectiveness has not been demonstrated in controlled studies. (कार्बिडोपा लेबल, चेतावनियां)

Nondepolarizing Muscle Relaxants In postmarketing experience there have been reports of a possible interaction between ketorolac tromethamineIV/IMand nondepolarizing muscle relaxants that resulted in apnea. (कीटोरोलैक लेबल, दवाओं के इंटरैक्शन)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

In Postanesthetic Use Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. (डॉक्साप्राम लेबल, चेतावनियां)

ATMEKSI may inhibit the effect of pyridostigmine bromide. (मेथोकार्बामोल लेबल, दवाओं के इंटरैक्शन)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (प्राज़ोसिन लेबल, दवाओं के इंटरैक्शन)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)